Butyrylcholinesterase inhibitors
AssigneeJal Therapeutics, Inc.
InventorsRoger A. Acey, Kensaku Nakayama
Life of this patent
Estimating the term…
Abstract
Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.
Claims19
A method of reducing a level of a β-amyloid peptide in the brain of a subject in need thereof, comprising administering an effective amount of di-n-butyl 2-chlorophenyl phosphate to the subject such that the di-n-butyl 2-chlorophenyl phosphate has a concentration of about 10−6 M to about 10−8 M in the brain of the subject.
A method of treating Alzheimer's disease in a subject in need thereof, comprising administering an effective amount of di-n-butyl 2-chlorophenyl phosphate to the subject such that the di-n-butyl 2-chlorophenyl phosphate has a concentration of about 10−6M to about 10−8M in the brain of the subject.
Dependencies are inferred from the claim text.